Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Simcere to Test TNRF2 mAb in Combination with MSD’s Keytruda for Solid Tumors

publication date: Mar 15, 2023

Nanjing Simcere Pharma will test its potential first-in-class anti-tumor necrosis factor receptor 2 (TNFR2) mAb with MSD's (Merck) anti-PD-1 therapy, Keytruda® (pembrolizumab). The trial, which will enroll patients with advanced solid tumors and cutaneous T-cell lymphoma (CTCL), will evaluate the safety and efficacy of SIM0235 as a monotherapy or in combination with Keytruda. A Simcere subsidiary, Simcere Zaiming, will conduct the trial and retain worldwide commercial rights to SIM0235. Formed earlier this year, Simcere Zaiming focuses on Simcere’s innovative cancer therapeutics. More details....

Stock Symbol: (HK: 2096)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China